Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-715 With or Without Nirogacestat in Relapsed/Refractory Multiple Myeloma
NCT04093596Phase 1Completed
- Sponsor
- Allogene Therapeutics
- Start
- Sep 2019
- Primary completion
- Jan 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALLO-715 in multiple myeloma (MM), sponsored by Allogene Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days, Overall safety profile and tolerability of ALLO-647 at 33 days and 1 more. Started Sep 2019; status: completed.
02
Drugs
ALLO-715
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04093596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093596.